DESITIN PHARMA A/S: Financial statements 2020
CVR: 19389006
Source: annual report 2020, Danish Business Authority
01/10/2019 – 30/09/2020
DESITIN PHARMA A/S (CVR 19389006) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 4,229,777 and a net result of DKK 430,256 compared with DKK 540,753 the year before. That is a decrease of 25.7% compared with the year before. Equity in the 2020 report amounted to DKK 6,089,091. The solvency ratio was 79.6%. The company had 3 employees in the financial year.
- Gross Profit
- DKK 4,229,777
- Profit/Loss
- DKK 430,256
- Equity
- DKK 6,089,091
- Total Assets
- DKK 7,646,834
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 4.2 mio. | 430 t. | 6.1 mio. | 3 |
| 2019 | - | 5.7 mio. | 541 t. | 5.7 mio. | 4 |
| 2018 | - | 6 mio. | 1.5 mio. | 5.1 mio. | - |
| 2017 | - | 4.6 mio. | 630 t. | 3.6 mio. | - |
| 2016 | - | 5.6 mio. | 1.2 mio. | 3.7 mio. | - |
Official annual report
How creditworthy is DESITIN PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of November 30, 2020, Eli Lønne has joined the board of directors of DESITIN PHARMA A/S.
As of November 30, 2020, Alexander Arnkværn Berg has left the board of directors of DESITIN PHARMA A/S.
As of November 30, 2020, Eli Lønne is registered as director of DESITIN PHARMA A/S.
As of November 30, 2020, Alexander Arnkværn Berg has stepped down as director of DESITIN PHARMA A/S.
As of February 17, 2020, Christoph Steinschulte has joined the board of directors of DESITIN PHARMA A/S.
As of February 17, 2020, Christian Eric Schmolck has left the board of directors of DESITIN PHARMA A/S.
About DESITIN PHARMA A/S
DESITIN PHARMA A/S is a Danish company of the type Aktieselskab based in København V, founded in 1996. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Eli Lønne. The board consists of Philipp Andreas Bloching (chair), Eli Lønne and Oliver Christoph. The company is owned by Desitin Arzneimittel GmbH. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 2,151,761 and a net result of DKK 288,733 compared with DKK 285,567 the year before. Equity in the 2025 report amounted to DKK 7,044,140.